Read More

Sanara Medtech Announced That Is Has Signed An Exclusive License Agreement With Tufts University To Develop And Commercialize Patented Technology Covering 18 Unique Collagen Peptides

As part of this agreement, Sanara has formed a new subsidiary, Sanara Collagen Peptides, LLC ("SCP"), and has issued 10% of SCP's outstanding units to Tufts. SCP has exclusive rights to develop and commercialize new

SMTI

Read More

Scribe Therapeutics Announced That Sanofi Has Exercised Its Option For A Second Target As Part Of The Companies’ Research Collaboration To Develop In Vivo CRISPR-based Therapeutics

Scribe announced its initial research collaboration with Sanofi for CRISPR-based cell therapies to address oncology indications in 2022, followed by an expansion of the collaboration in 2023 to

SNY